David C. W. Lau, MD, PhD, FRCPC - Endocrinology and Metabolism

Dr. David Lau reviews medical content for Healthwise, a nonprofit organization with a mission to help people make better health decisions. Dr. Lau is a practicing endocrinologist who specializes in diabetes, obesity, and lipid disorders. He is an active researcher, educator, and clinician, and he has published over 100 scientific papers. Dr. Lau is also involved in giving public lectures and forums on diabetes, lipids, and obesity. He spearheaded the evidence-based Obesity Canada clinical practice guidelines for the management and prevention of obesity in adults and children. He has also served as an expert panel member on the WHO-International Obesity Task Force and the 1998, 2003, and 2007 Canadian Diabetes Association Clinical Practice Guidelines for Body Weight Classification. Dr. Lau is a Professor of Medicine, Biochemistry, and Molecular Biology, and Chair of the Diabetes and Endocrine Research Group at the University of Calgary.

Education and Training

MD: University of Toronto, Toronto, ON

PhD: University of Toronto, Toronto, ON

Internship and Residency in Internal Medicine and Endocrinology: Harvard Medical School, Boston, MA

Residency and Fellowship in Internal Medicine and Endocrinology: University of Toronto, Toronto, ON

Certifications

American Board of Internal Medicine

Royal College of Physicians and Surgeons of Canada

Academic Appointments

University of Calgary, Calgary, AL:

  • Professor, Departments of Medicine, Biochemistry, and Molecular Biology
  • Adjunct Professor, Faculty of Kinesiology

Financial Disclosure

The final approval of Healthwise content is always made by a clinician with no financial conflicts.

Research grant support and compensation for consulting received from:

  • Abbott Laboratories.
  • Allergan
  • AstraZeneca.
  • Bayer
  • Boehringer-Ingelheim
  • Bristol Myers Squibb.
  • Covidien
  • Dainippon
  • Eli Lilly Pharmaceuticals.
  • GlaxoSmithKline.
  • Janssen Inc.
  • Merck and Co.
  • Novartis
  • Novo Nordisk.
  • Oryx.
  • Pfizer.
  • Roche.
  • Sanofi
  • Solvay.
  • Valeant

Current as of: June 27, 2014